文献速递乳腺癌支持与姑息治疗

蒽环类药物治疗的心脏毒性效应:证据何在,潜在危害又有哪些?

Cardiotoxic effects of anthracycline-based therapy: what is the evidence and what are the potential harms?
PubMed 文献 · Lancet Oncol · 2017-07-26

本文综述多柔比星等蒽环类药物治疗乳腺癌成人幸存者的心脏毒性问题。对于既往蒽环类累计剂量有限(即总累计剂量240 mg/m2)或接受有限剂量蒽环类后序贯曲妥珠单抗方案者,目前缺乏基于证据的监测与预防指南;部分心脏肿瘤学与心脏影像机构建议加强监测、检测生物标志物并启用心脏保护药物,但医学化与医疗费用增加是潜在危害,尚需进一步研究。

要点

  • 对累计剂量240 mg/m2或有限剂量蒽环类后序贯曲妥珠单抗者,尚无基于证据的监测与预防指南
  • 部分国家与国际心脏肿瘤学及心脏影像机构建议加强心脏监测、检测生物标志物,部分情况启用心脏保护药物
  • 此类做法可能导致医学化(对亚临床心脏问题在缺乏高级别证据时定义并治疗)及医疗费用增加

核心结论

  • 对既往蒽环类累计剂量有限(即总累计剂量240 mg/m2)或有限剂量蒽环类后序贯曲妥珠单抗方案的乳腺癌成人幸存者,尚无基于证据的监测与预防指南;需进一步研究评估扩大心脏监测、替代心脏生物标志物及预防性心脏保护治疗的长期获益、危害与价值。

研究设计与样本

  • 本文为综述,讨论多柔比星等蒽环类药物的已知心脏毒性效应及相关证据与潜在危害。

主要发现

  • 部分国家与国际心脏肿瘤学及心脏影像机构建议在治疗期间或治疗后加强心脏监测、检测心脏生物标志物及其他替代终点,部分情况下对无症状女性启用心脏保护药物治疗。
  • 此类做法的两个非预期潜在危害为医学化(对亚临床心脏问题在缺乏高级别证据表明可降低后续心力衰竭或心源性死亡发生率的情况下进行定义和治疗)和医疗费用增加(所提供照护的价值未知时)。
  • 现有心脏肿瘤学或影像指南推荐是带来更大价值,还是造成更多痛苦并降低健康相关生活质量,尚不清楚。

临床怎么用

  • 作者指出,需进一步研究评估扩大心脏监测、使用替代心脏生物标志物及预防性心脏保护治疗在蒽环类暴露有限的无症状女性中的长期获益、危害与价值。

局限性

  • 现有心脏肿瘤学或影像指南推荐是带来更大价值,还是造成更多痛苦并降低健康相关生活质量,尚不清楚。
  • 进一步研究是必要的,以评估扩大心脏监测、使用替代心脏生物标志物及预防性心脏保护治疗的长期获益、危害与价值。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Despite the known cardiotoxic effects of doxorubicin and other anthracyclines, no evidence-based guidelines exist for the surveillance and prevention of chemotherapy-induced cardiotoxicity in adult survivors of breast cancer who have had limited previous doses of anthracyclines (ie, total cumulative dose 240 mg/m2), or limited-dose anthracyclines followed by trastuzumab-based regimens. Nonetheless, some national and international cardio-oncology and cardiac-imaging organisations recommend increased cardiac surveillance during or after treatment, measurement of cardiac biomarkers and other surrogate endpoints, and in some cases initiation of cardioprotective drug therapy in asymptomatic women. However, two unintended potential harms of such approaches are medicalisation (definition and treatment of subclinical heart problems without high-level evidence for a consequent reduction in the incidence of subsequent heart failure or cardiac deaths) and increased health-care costs when the value of providing that care is unknown. Whether existing cardio-oncology or imaging guideline recommendations will provide increased value or cause increased distress and lower health-related quality of life is unknown. Further research is needed to assess the long-term benefits, harms, and value of expanded cardiac surveillance, use of surrogate cardiac biomarkers, and prophylactic cardioprotective therapy in asymptomatic women with limited exposure to anthracyclines.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Levis BE, Binkley PF, Shapiro CL, et al. Cardiotoxic effects of anthracycline-based therapy: what is the evidence and what are the potential harms? Lancet Oncol. 2017. PMID: 28759384. doi:10.1016/S1470-2045(17)30535-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。